Ipamorelin 5mg

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue derived from GHRP-1 through structural optimisation. It was the first selective growth hormone-releasing peptide (GHRP) receptor agonist developed, demonstrating selectivity similar to that of growth hormone-releasing hormone (GHRH) for stimulating growth hormone release.

In biochemical and cellular research systems, ipamorelin acts as an agonist at the ghrelin/growth hormone secretagogue receptor (GHSR-1a) expressed on pituitary somatotroph cells. Unlike earlier GHRP compounds such as GHRP-6 and GHRP-2, ipamorelin exhibits a distinct selectivity profile: experimental studies have demonstrated that it does not release adrenocorticotropic hormone (ACTH) or cortisol at growth hormone-stimulating concentrations. This selectivity makes ipamorelin a valuable research tool for investigating GH secretion pathways independently of hypothalamic-pituitary-adrenal (HPA) axis activation. In animal models, ipamorelin has been reported to induce longitudinal bone growth in a dose-dependent manner under controlled experimental conditions.

Applications in Research

Investigation of GHSR-1a receptor binding, selectivity, and signalling pathways

Study of growth hormone secretagogue mechanisms independent of HPA axis activation

Research into pituitary somatotroph function and GH release dynamics

In vitro and in vivo comparison with other GHRP compounds (GHRP-2, GHRP-6, Hexarelin)

Models examining GH/IGF-1 axis regulation and bone growth signalling

Use as a selective reference compound in neuroendocrine and peptide signalling research

Precautions & Notes

Experimental behaviour of MOTS-c is influenced by metabolic state, cell type, and peptide concentration.

Buffer composition, pH, and ionic strength may affect peptide stability.

Appropriate controls are recommended.

Intended strictly for laboratory research use.